You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest SGLT2 Inhibitors Articles
Popular SGLT2 Inhibitors Articles
Highly Recommended SGLT2 Inhibitors Articles
Send a link to this page to your friends and colleagues.
A new, first-in-its-class drug for type 2 diabetes has just been approved by the Food and Drug Administration. Invokana works by blocking re-absorption of glucose by the kidneys and stimulating urination, which removes glucose from the bloodstream.
In the course of nine clinical trials that included over 10,000 patients, the drug improved both A1c and fasting glucose levels. In addition, the drug helps reduce weight and blood pressure. With a regimen that includes diet and exercise, the drug can be taken by itself or in combination with other drugs including insulin, metformin, and others.
Invokana is not intended for those with type1 diabetes, end-stage or severe kidney disease, or people undergoing dialysis. Additional FDA-mandated studies will investigate the drug's effects on the heart, pancreas and other parts of the body; monitoring for malignancies, a bone safety study, and two studies in children.
Invokana, a tablet, is the first of a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. The most common side effects are vaginal yeast and urinary tract infections, thought to be caused by increased urination. As the drug encourages urination, it can also lead to a sudden fall in blood pressure when a patient stands, although this is most common in the first three months of therapy.
The drug is manufactured by Janssen Pharmaceuticals, part of Johnson & Johnson.
1 comment - Jun 27, 2013
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.